Influence of Ketoconazole on the Pharmacokinetics of Romidepsin in Patients With Advanced Cancer

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 1, 2011

Primary Completion Date

January 1, 2012

Study Completion Date

January 1, 2012

Conditions

Hematologic MalignancyMalignant Lymphoma

Interventions

DRUG

Romidepsin

Romidepsin 8 mg/m\^2 intravenous infused over 4 hours on Day 1 and Day 8.

DRUG

Ketoconazole

Ketoconazole 400 mg oral once daily on Days 4-8

Trial Locations (3)

Florida Cancer Specialists, Sarasota

Sarah Cannon Research Institute, Nashville

Sarah Cannon Research UK, London